These results identified the TNF-α/TNFAIP3 axis as a target of HDIs and were in line with previous literature demonstrating that HDIs can regulate inflammation at doses that are 10–100-fold lower than those used for the treatment of cancer [51]. The gene discussed is TNF; the disease is cancer.